Unit 01-02 & 09-12, 8th Floor, Building 22, No. 388 Xinping Street, Suzhou Industrial Park, Suzhou Area, Jiangsu Pilot Free Trade Zone, China
One-stop Organoid Model Validation
bioGenous BIOTECH specializes in organoid construction, drug testing, and multi-omics analysis, offering comprehensive solutions ranging from organoid construction, expansion, identification, drug intervention, sample preparation, NGS sequencing, to data analysis and visualization. We provide customized one-on-one research plans tailored to our clients' needs, delivering clear research paradigms to accelerate scientific progress. Our services support personalized medicine and precision medicine, simplifying project initiation and facilitating paper publication.
Drug Screening and Mechanism Analysis Based on NAFLD Organoid Models: Researchers utilized non-alcoholic fatty liver disease (NAFLD) organoid models to screen 17 candidate drugs, identifying 5 drugs that improved hepatic steatosis across different NAFLD organoid models. Subsequently, transcriptome sequencing (Bulk RNA-seq) was performed on organoids treated with these positive drugs, revealing significant differences in their mechanisms of action and cellular adverse effects.
（Delilah Hendriks, et al. Nature Biotechnology, 2023）
Multi-omics Reveals Cardiac Organoids as an Effective In Vitro Model for Viral Infection: Using SARS-CoV-2 (Wuhan Hu-1) and Omicron BA.5 to infect iPSC-derived cardiac organoids, immunofluorescence staining demonstrated that the virus could infect cardiomyocytes and endothelial cells, with viral RNA replication occurring within the cells. Transcriptomic analysis of organoids before and after infection showed that SARS-CoV-2 infection upregulated genes related to cardiomyocyte injury, endothelial cell injury, antiviral responses, and pro-inflammatory reactions, consistent with transcriptomic sequencing results from clinical samples.
（Weijie Wang, et al. Virologica sinica, 2023）
Colon Polyp Organoids Facilitate Drug Repurposing Strategy Development: Researchers constructed a colon polyp organoid library and conducted high-throughput screening of 139 small molecule drugs, discovering that metformin significantly inhibits colon polyp organoids. Transcriptome sequencing (Bulk RNA-seq) further confirmed that, compared to the control group, metformin treatment reduced Wnt signaling activity and stemness-related gene expression levels in colon polyp organoids, thereby suppressing organoid growth. These findings were also validated in a mouse model of colon polyps.
